Edwards Lifesciences Corporation’s Stock Price Soars to $69.38, Registering a Positive Leap of 1.64%

Edwards Lifesciences Corporation (EW)

69.38 USD +1.12 (+1.64%) Volume: 4.86M

Edwards Lifesciences Corporation’s stock price sees a positive momentum, trading at 69.38 USD with a rise of +1.64% this session, backed by a robust trading volume of 4.86M, despite a YTD percentage change of -9.01%.

Latest developments on Edwards Lifesciences Corporation

Today, Edwards Lifesciences’ stock price is on the move following a series of key events. The company recently acquired JC Medical from Genesis MedTech, adding to its portfolio of aortic valve disease solutions. This acquisition comes as Edwards continues its focus on valve-related M&A activities, including purchasing a promising TAVR startup. The company’s strategic moves have caught the attention of investors, with Brookstone Capital Management and Sumitomo Mitsui Trust Holdings Inc. both adjusting their stock holdings in Edwards Lifesciences Co. (NYSE:EW). Raymond James & Associates also holds a substantial $168.60 million in stock holdings for the company. Edwards Lifesciences is putting its critical care spinoff cash to good use, further solidifying its position in the market.

A look at Edwards Lifesciences Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Edwards Lifesciences Corporation, a company specializing in treating late-stage cardiovascular disease, has received mixed ratings in the Smartkarma Smart Scores. While scoring well in areas such as value, growth, resilience, and momentum, the company falls short in the dividend category. This indicates a positive long-term outlook for the company overall, with strengths in various key factors contributing to its success.

With a solid foundation in product development and global supply, Edwards Lifesciences is positioned to continue its growth and resilience in the market. Despite some areas for improvement, such as in the dividend score, the company’s overall outlook remains promising. Investors may find value in considering the company’s potential for long-term success based on its performance in key areas as indicated by the Smartkarma Smart Scores.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma